Literature DB >> 19010856

Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression.

Eung-Sirk Lee1, Dae-Soon Son, Sung-Hyun Kim, Jinseon Lee, Jisuk Jo, Joungho Han, Heesue Kim, Hyun Joo Lee, Hye Young Choi, Youngja Jung, Miyeon Park, Yu Sung Lim, Kwhanmien Kim, YoungMog Shim, Byung Chul Kim, Kyusang Lee, Nam Huh, Christopher Ko, Kyunghee Park, Jae Won Lee, Yong Soo Choi, Jhingook Kim.   

Abstract

PURPOSE: One of the main challenges of lung cancer research is identifying patients at high risk for recurrence after surgical resection. Simple, accurate, and reproducible methods of evaluating individual risks of recurrence are needed. EXPERIMENTAL
DESIGN: Based on a combined analysis of time-to-recurrence data, censoring information, and microarray data from a set of 138 patients, we selected statistically significant genes thought to be predictive of disease recurrence. The number of genes was further reduced by eliminating those whose expression levels were not reproducible by real-time quantitative PCR. Within these variables, a recurrence prediction model was constructed using Cox proportional hazard regression and validated via two independent cohorts (n = 56 and n = 59).
RESULTS: After performing a log-rank test of the microarray data and successively selecting genes based on real-time quantitative PCR analysis, the most significant 18 genes had P values of <0.05. After subsequent stepwise variable selection based on gene expression information and clinical variables, the recurrence prediction model consisted of six genes (CALB1, MMP7, SLC1A7, GSTA1, CCL19, and IFI44). Two pathologic variables, pStage and cellular differentiation, were developed. Validation by two independent cohorts confirmed that the proposed model is significantly accurate (P = 0.0314 and 0.0305, respectively). The predicted median recurrence-free survival times for each patient correlated well with the actual data.
CONCLUSIONS: We have developed an accurate, technically simple, and reproducible method for predicting individual recurrence risks. This model would potentially be useful in developing customized strategies for managing lung cancer.

Entities:  

Mesh:

Year:  2008        PMID: 19010856     DOI: 10.1158/1078-0432.CCR-07-4937

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  133 in total

1.  Network-induced classification kernels for gene expression profile analysis.

Authors:  Ofer Lavi; Gideon Dror; Ron Shamir
Journal:  J Comput Biol       Date:  2012-06       Impact factor: 1.479

2.  Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer.

Authors:  Jin-Soo Kim; Edward S Kim; Diane Liu; J Jack Lee; Luisa Solis; Carmen Behrens; Scott M Lippman; Waun Ki Hong; Ignacio I Wistuba; Ho-Young Lee
Journal:  Cancer       Date:  2011-09-22       Impact factor: 6.860

3.  Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types.

Authors:  Matthew D Wilkerson; Xiaoying Yin; Katherine A Hoadley; Yufeng Liu; Michele C Hayward; Christopher R Cabanski; Kenneth Muldrew; C Ryan Miller; Scott H Randell; Mark A Socinski; Alden M Parsons; William K Funkhouser; Carrie B Lee; Patrick J Roberts; Leigh Thorne; Philip S Bernard; Charles M Perou; D Neil Hayes
Journal:  Clin Cancer Res       Date:  2010-07-19       Impact factor: 12.531

4.  Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data--methods and preliminary results.

Authors:  Olivier Gevaert; Jiajing Xu; Chuong D Hoang; Ann N Leung; Yue Xu; Andrew Quon; Daniel L Rubin; Sandy Napel; Sylvia K Plevritis
Journal:  Radiology       Date:  2012-06-21       Impact factor: 11.105

5.  Chemokine-like factor 1: A promising therapeutic target in human diseases.

Authors:  Xiaopeng Cai; Jingwen Deng; Qianqian Ming; Huiqiang Cai; Zhi Chen
Journal:  Exp Biol Med (Maywood)       Date:  2020-07-26

6.  Metabolic enzymes expressed by cancer cells impact the immune infiltrate.

Authors:  Gautier Stoll; Margerie Kremer; Normal Bloy; Adrien Joseph; Maria Castedo; Guillaume Meurice; Christophe Klein; Lorenzo Galluzzi; Judith Michels; Guido Kroemer
Journal:  Oncoimmunology       Date:  2019-03-30       Impact factor: 8.110

Review 7.  Update in lung cancer 2008.

Authors:  Sarita Dubey; Charles A Powell
Journal:  Am J Respir Crit Care Med       Date:  2009-05-15       Impact factor: 21.405

8.  Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers.

Authors:  Sophie Rousseaux; Alexandra Debernardi; Baptiste Jacquiau; Anne-Laure Vitte; Aurélien Vesin; Hélène Nagy-Mignotte; Denis Moro-Sibilot; Pierre-Yves Brichon; Sylvie Lantuejoul; Pierre Hainaut; Julien Laffaire; Aurélien de Reyniès; David G Beer; Jean-François Timsit; Christian Brambilla; Elisabeth Brambilla; Saadi Khochbin
Journal:  Sci Transl Med       Date:  2013-05-22       Impact factor: 17.956

9.  Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas.

Authors:  Alexis Desrichard; Fengshen Kuo; Diego Chowell; Ken-Wing Lee; Nadeem Riaz; Richard J Wong; Timothy A Chan; Luc G T Morris
Journal:  J Natl Cancer Inst       Date:  2018-12-01       Impact factor: 13.506

10.  A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients.

Authors:  Elena Martínez-Terroba; Carmen Behrens; Fernando J de Miguel; Jackeline Agorreta; Eduard Monsó; Laura Millares; Cristina Sainz; Miguel Mesa-Guzman; José Luis Pérez-Gracia; María Dolores Lozano; Javier J Zulueta; Ruben Pio; Ignacio I Wistuba; Luis M Montuenga; María J Pajares
Journal:  J Pathol       Date:  2018-06-20       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.